[1] |
Dirks PB.
Brain tumor stem cells: bringing order to the chaos of brain cancer[J]. J Clin OncolJ Clin Oncol, 2008, 26(17): 2916-2924.
doi: 10.1200/JCO.2008.17.6792 |
[2] |
Louis DN, Perry A, Reifenberger G, et al.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta NeuropatholActa Neuropathol, 2016, 131(6): 803-820.
doi: 10.1007/s00401-016-1545-1 |
[3] |
Glioma Meta-analysis Trialists (GMT) Group.
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials[J]. LancetLancet, 2002, 359(9311): 1011-1018.
doi: 10.1016/S0140-6736(02)08091-1 |
[4] |
Wu HM, Huang SC, Choi Y, et al.
A Modeling Method to Improve Quantitation of Fluorodeoxyglucose Uptake in Heterogeneous Tumor Tissue[J]. J Nucl MedJ Nucl Med, 1995, 36(2): 297-306.
|
[5] |
Hutterer M, Nowosielski M, Putzer D, et al.
O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma[J]. J Nucl MedJ Nucl Med, 2011, 52(6): 856-864.
doi: 10.2967/jnumed.110.086645 |
[6] |
Jeong SY, Lim SM.
Comparison of 3′-deoxy-3′-[18F] fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma[J]. Nucl Med BiolNucl Med Biol, 2012, 39(7): 977-981.
doi: 10.1016/j.nucmedbio.2012.02 |
[7] |
理东丽, 许乙凯, 王全师, 等.
11C-MET和18F-FDG PET/CT对胶质瘤诊断的价值比较[J]. 核技术核技术, 2011, 34(2): 151-155.
Li DL, Xu YK, Wang QS, et al. Comparative PET/CT study with 11C-MET and 18F-FDG for diagnosing glioma[J]. Nucl TechNucl Tech, 2011, 34(2): 151-155. |
[8] |
Oehme L, Perick M, Beuthien-Baumann B, et al.
Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson's disease[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2011, 38(8): 1550-1559.
doi: 10.1007/s00259-011-1819-8 |
[9] |
Fueger BJ, Czernin J, Cloughesy T, et al.
Correlation of 6-18F-Fluoro-l-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas[J]. J Nucl MedJ Nucl Med, 2010, 51(10): 1532-1538.
doi: 10.2967/jnumed.110.078592 |
[10] |
Tripathi M, Sharma R, D'Souza M, et al.
Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas[J]. Clin Nucl MedClin Nucl Med, 2009, 34(12): 878-83.
doi: 10.1097/RLU.0b013e3181becfe0 |
[11] |
黄世明, 罗燕薇, 李彦峰, 等.
18F-FDOPA与18F-FDG PET/CT诊断脑肿瘤的系统评价[J]. 武警医学武警医学, 2017, 28(6): 573-577.
doi: 10.14010/j.cnki.wjyx.2017.06.011 Huang SM, Luo YW, Li YF, et al. A systematic comparison of 18F-FDOPA PET/CT with 18F-FDG PET/CT for diagnosis of brain tumors[J]. Med J Chin PAPMed J Chin PAP, 2017, 28(6): 573-577. doi: 10.14010/j.cnki.wjyx.2017.06.011 |
[12] |
Liu RS, Chang CP, Chu LS, et al.
PET imaging of brain astrocytoma with 1-11C-acetate[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2006, 33(4): 420-427.
doi: 10.1007/s00259-005-0023-0 |
[13] |
Tsuchida T, Takeuchi H, Okazawa H, et al.
Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET[J]. Nucl Med BiolNucl Med Biol, 2008, 35(2): 171-176.
doi: 10.1016/j.nucmedbio.2007.11.004 |
[14] |
Yamamoto Y, Nishiyama Y, Kimura N, et al.
11C-Acetate PET in the Evaluation of Brain Glioma: Comparison with 11C-Methionine and 18F-FDG-PET[J]. Mol Imaging BiolMol Imaging Biol, 2008, 10(5): 281-287.
doi: 10.1007/s11307-008-0152-5 |
[15] |
Kim S, Kim D, Kim SH, et al.
The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2018, 45(6): 1012-1020.
doi: 10.1007/s00259-018-3948-9 |
[16] |
Wardak M, Schiepers C, Cloughesy TF, et al.
18F-FLT and 18F-FDOPA PET Kinetics in Recurrent Brain Tumors[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2014, 41(6): 1199-1209.
doi: 10.1007/s00259-013-2678-2 |
[17] |
Shields AF, Grierson JR, Dohmen BM, et al.
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography[J]. Nat MedNat Med, 1998, 4(11): 1334-1336.
doi: 10.1038/3337 |
[18] |
Saga T, Kawashima H, Araki N, et al.
Evaluation of Primary Brain Tumors With FLT-PET: Usefulness and Limitations[J]. Clin Nucl MedClin Nucl Med, 2006, 31(12): 774-780.
doi: 10.1097/01.rlu.0000246820.14892.d2 |
[19] |
Hong IK, Kim JH, Ra YS, et al.
Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor[J]. J Comput Assist TomogrJ Comput Assist Tomogr, 2011, 35(6): 679-684.
doi: 10.1097/RCT.0b013e3182345b0e |
[20] |
Weber MA, Henze M, Tüttenberg J, et al.
Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?[J]. Invest RadiolInvest Radiol, 2010, 45(12): 755-768.
doi: 10.1097/RLI.0b013e3181ec9db0 |
[21] |
Lodge MA, Holdhoff M, Leal JP, et al.
Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma[J]. J Nucl MedJ Nucl Med, 2017, 58(3): 393-398.
doi: 10.2967/jnumed.116.178434 |
[22] |
Collet S, Valable S, Constans JM, et al.
[18F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas[J]. NeuroImage ClinNeuroImage Clin, 2015, 8: 448-454.
doi: 10.1016/j.nicl.2015.05.012 |
[23] |
Yamamoto Y, Ono Y, Aga F, et al.
Correlation of 18F-FLT Uptake with Tumor Grade and Ki-67 Immunohistochemistry in Patients with Newly Diagnosed and Recurrent Gliomas[J]. J Nucl MedJ Nucl Med, 2012, 53(12): 1911-1915.
doi: 10.2967/jnumed.112.104729 |
[24] |
Brockenbrough JS, Souquet T, Morihara JK, et al.
Tumor 3'-Deoxy-3'-18F-Fluorothymidine (18F-FLT) Uptake by PET Correlates with Thymidine Kinase 1 Expression: Static and Kinetic Analysis of 18F-FLT PET Studies in Lung Tumors[J]. J Nucl MedJ Nucl Med, 2011, 52(8): 1181-1188.
doi: 10.2967/jnumed.111.089482 |
[25] |
Spence AM, Muzi M, Link JM, et al.
NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy Studies[J]. Mol Imaging BiolMol Imaging Biol, 2009, 11(5): 343-355.
doi: 10.1007/s11307-009-0215-2 |
[26] |
Enslow MS, Zollinger LV, Morton KA, et al.
Comparison of 18F-Fluorodeoxyglucose and 18F-Fluorothymidine PET in Differentiating Radiation Necrosis from Recurrent Glioma[J]. Clin Nucl MedClin Nucl Med, 2012, 37(9): 854-861.
doi: 10.1097/RLU.0b013e318262c76a |
[27] |
Mitamura K, Yamamoto Y, Kudomi N, et al.
Intratumoral heterogeneity of 18F-FLT uptake predicts proliferation and survival in patients with newly diagnosed gliomas[J]. Ann Nucl MedAnn Nucl Med, 2017, 31(1): 46-52.
doi: 10.1007/s12149-016-1129-0 |
[28] |
Chen W, Delaloye S, Silverman DHS, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation with [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study[J]. J Clin OncolJ Clin Oncol, 2007, 25(30): 4714-4721.
doi: 10.1200/JCO.2006.10.5825 |
[29] |
Zhao F, Cui YF, Li MH, et al.
Prognostic value of 3’-Deoxy-3’-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas[J]. Nucl Med BiolNucl Med Biol, 2014, 41(8): 710-715.
doi: 10.1016/j.nucmedbio.2014.04.134 |
[30] |
Pope WB, Young JR, Ellingson BM.
Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy[J]. Curr Neurol Neurosci RepCurr Neurol Neurosci Rep, 2011, 11(3): 336-344.
doi: 10.1007/s11910-011-0179-x |
[31] |
Zhao F, Li MH, Wang ZH, et al. 18F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI[J/OL]. PLoS One, 2015, 10(3): e0118769 [2018−08−01]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118769. DOI: 10.1371/journal.pone.0118769. |
[32] |
Schwarzenberg J, Czernin J, Cloughesy TF, et al.
3'-Deoxy-3'-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab[J]. J Nucl MedJ Nucl Med, 2012, 53(1): 29-36.
doi: 10.2967/jnumed.111.092387 |
[33] |
Bollineni VR, Collette S, Liu Y.
Functional and molecular imaging in cancer drug development[J]. Chin Clin OncolChin Clin Oncol, 2014, 3(2): 17-.
doi: 10.3978/j.issn.2304-3865.2014.05.05 |
[34] |
Idema AJS, Hoffmann AL, Boogaarts HD, et al.
3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients[J]. J Nucl MedJ Nucl Med, 2012, 53(12): 1904-1910.
doi: 10.2967/jnumed.112.105544 |
[35] |
Li ZP, Yu Y, Zhang HH, et al.
A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence[J]. Nucl Med CommunNucl Med Commun, 2015, 36(7): 695-701.
doi: 10.1097/MNM.0000000000000302 |
[36] |
Belohlavek O, Fencl P, Majovsky M, et al.
FLT-PET in previously untreated patients with low-grade glioma can predict their overall survival[J]. Nucl Med RevNucl Med Rev, 2014, 17(1): 7-12.
doi: 10.5603/NMR.2014.0003 |
[37] |
Chen W, Cloughesy T, Kamdar N, et al.
Imaging Proliferation In Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG[J]. J Nucl MedJ Nucl Med, 2005, 46(6): 945-952.
|
[38] |
Toyota Y, Miyake K, Kawai N, et al. Comparison of 4′-[methyl-11C]thiothymidine (11C-4DST) and 3′-deoxy-3′-[18F] fluorothymidine (18F-FLT) PET/CT in human brain glioma imaging[J/OL]. EJNMMI Res, 2015, 5: 7[2018−08-01]. https://www.ncbi.nlm.nih.gov/pubmed/25853013. DOI: 10.1186/s13550−015−0085−3. |